Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310990 | 0.73 | PSEN1 (0.41) | — | |
| SCHEMBL29987766 | 0.71 | ALDH1A1 (0.35) | IDO1 | |
| SCHEMBL2009460 | 0.71 | ALDH1A1 (0.35) | IDO1 | |
| SCHEMBL20099818 | 0.68 | IDO1 (0.31) | IDO1 | |
| SCHEMBL11898758 | 0.67 | MAPK1 (0.41) | L3MBTL1IDO1 | |
| SCHEMBL1500853 | 0.67 | — | — | |
| SCHEMBL28720437 | 0.67 | IDO1 (0.31) | IDO1 | |
| SCHEMBL11899073 | 0.66 | HTR2C (0.43) | L3MBTL1IDO1 | |
| SCHEMBL31288016 | 0.66 | PNMT (0.43) | IDO1 | |
| SCHEMBL5430781 | 0.65 | SLC6A2 (0.41) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408450-B1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8350084-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2295417-B1 | Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound | BRISTOL MYERS SQUIBB CO (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471769-A1 | Process for preparing a benzonitrile derivative | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120088925-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| EP-2408450-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8093276-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8084477-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2295417-A1 | Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound | Bristol-Myers Squibb Company (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2205575-B1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010107435-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-2205575-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| WO-2009058552-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | APP, BACE1, IAPP | GAA 83/4885L3MBTL1 4535/4885IDO1 2676/4885 |
| US-20120088925-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | APP, BACE1, IAPP | GAA 83/4885L3MBTL1 4535/4885IDO1 2676/4885 |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, APBA1 | GAA 754/4885L3MBTL1 706/4885IDO1 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.